Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.77 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.77 |
| ▸ | OXTR | P30559 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6627050 | 0.87 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL6623504 | 0.85 | AVPR2 (0.76) | AVPR2AVPR1AOXTR | |
| SCHEMBL7225460 | 0.83 | AVPR2 (0.68) | AVPR2AVPR1AOXTR | |
| SCHEMBL6624422 | 0.83 | AVPR2 (0.73) | AVPR2AVPR1AOXTR | |
| SCHEMBL7333775 | 0.80 | AVPR2 (0.50) | AVPR2AVPR1AOXTR | |
| SCHEMBL6624625 | 0.80 | AVPR2 (0.68) | AVPR2AVPR1AOXTR | |
| SCHEMBL6618394 | 0.78 | AVPR2 (0.71) | AVPR2AVPR1AOXTR | |
| SCHEMBL7234666 | 0.77 | AVPR2 (0.81) | AVPR2AVPR1AOXTR | |
| SCHEMBL6628600 | 0.77 | AVPR2 (0.81) | AVPR2AVPR1AOXTR | |
| SCHEMBL7333588 | 0.77 | AVPR2 (0.47) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000062-B1 | TRICYCLIC VASOPRESSIN AGONISTS | WYETH CORP (US) | 2004-09-22 | — | — | EP | claimed |
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | claimed |
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | claimed |
| US-6831079-B1 | Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone | AMERICAN CYANAMID COMPANY | 2004-12-14 | — | — | US | disclosed |
| EP-1000062-B1 | TRICYCLIC VASOPRESSIN AGONISTS | WYETH CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | disclosed |
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |